Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 1997

View Archived Issues

British Biotech: Q1 1997 highlights

Yoshitomi licenses immunosuppressant to Novartis

Cambridge NeuroScience awarded sixteenth SBIR grant

Improved efficacy of MEN-10755 related to apoptosis?

NIH approves study of marijuana in HIV-infected patients

GM-237354: a new antifungal sordarin derivative from Glaxo Wellcome

KBT-3022: pharmacokinetics and pharmacological effects in guinea pigs

Vanguard Medica and Abbott collaborate on development of new oral asthma therapy

Alza, Alkermes to codevelop RMP-7 for brain-specific drug delivery

Phase II results for IDEC-C2B8 in NHL

CV Therapeutics moves ranolazine to phase III

Combined pharmacological/genetic strategy for HIV shows promise

Gonal-F approved for marketing in U.S.

Antiproliferative activity of simvastatin demonstrated against human gliomas

Mutual Recognition Procedure concludes for Nasonex

DCLHb evaluated in critically ill patients

Oral desmopressin evaluated in bed-wetting children

Eltenac efficacy demonstrated in osteoarthritis

NIH grant to support development of CytRx's Protox

Preclinical data indicate effectiveness of Sertoli cells in neural regeneration

CellPro seeks new indication for CEPRATE SC System

FDA actively reviewing TOBI

Bacterial and viral infections focus of ArQule-RiboGene collaboration

Cancer cells being used to treat cancer

Briana Bio-Tech licenses peptide technology for chronic MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...